SCHEDULE: Forbion Funds Update NewAmsterdam Pharma Ownership

Forbion Capital Partners and related entities have filed an amendment to their beneficial ownership in NewAmsterdam Pharma Company N.V., reporting an aggregate stake of 8.3%.

Summary

• This document is Amendment No. 5 to the Schedule 13D originally filed on June 30, 2023, concerning the Ordinary Shares of NewAmsterdam Pharma Company N.V.
• Forbion Capital Fund IV Cooperatief U.A. and Forbion IV Management B.V. are deemed to beneficially own 4,668,889 Ordinary Shares, representing approximately 4.1% of the outstanding shares.
• Forbion Growth Opportunities Fund I Cooperatief U.A. and Forbion Growth Management B.V. are deemed to beneficially own 4,648,025 Ordinary Shares, representing approximately 4.1% of the outstanding shares.
• ForGrowth NAP B.V. is deemed to beneficially own an aggregate of 9,316,914 Ordinary Shares, representing approximately 8.3% of the outstanding shares.
• The reported percentages are based on 112,628,458 Ordinary Shares outstanding, as disclosed by NewAmsterdam Pharma Company N.V. in its Quarterly Report on Form 10-Q filed on August 6, 2025.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine update of beneficial ownership, indicating a significant, continued stake by a major investor. While not explicitly positive news, it doesn't contain any negative information or divestment, suggesting ongoing commitment.

Future Outlook

NA

Industry Context

This filing indicates continued significant investment by Forbion, a prominent European life sciences venture capital firm, in NewAmsterdam Pharma, a company focused on cardiovascular and metabolic diseases. Such substantial stakes by specialized funds often signal confidence in the company's long-term prospects within the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.

Key Dates

Recommendation

This Schedule 13D Amendment No. 5 is a routine disclosure of beneficial ownership by Forbion Capital Partners and its related entities in NewAmsterdam Pharma Company N.V. It confirms a substantial, ongoing stake of 8.3% by a specialized life sciences investor. While the continued significant ownership by a reputable fund can be viewed as a positive signal of confidence, the filing itself does not contain new material information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. It primarily updates the reporting of an existing significant position. Therefore, a 'hold' recommendation is appropriate as there's no new catalyst for 'buy' or 'sell' based solely on this filing.

Keywords

NewAmsterdam Pharma, Forbion Capital Partners, Forbion Growth, Beneficial Ownership, Schedule 13D, Ordinary Shares, Biotechnology, Pharmaceuticals, Investment